1 Correction to: PharmacoEconomics (2018) 36:39–49 https://doi.org/10.1007/s40273-017-0568-3
Page 41, Column 1, Section 3.1, paragraph 2, 1st sentence which
Previously read:
“In patients who had no prior lines of therapy for advanced disease, an investigator-assessed improvement in median progression-free survival (PFS) was 2.5 months (6.6 months, 95% confidence interval [CI] 4.1–8.3) in the OlaDox arm versus 4.1 months (95% CI 2.8–5.4) in the doxorubicin arm (hazard ratio [HR] 0.672; p = 0.0615) [8].”
Should read:
“In patients who had no prior lines of therapy for advanced disease, an investigator-assessed improvement in median progression-free survival (PFS) for OlaDox was 2.5 months [6.6 months (95% CI 3.1–9.3) in the OlaDox arm versus 4.1 months (95% CI 2.8–6.2) in the doxorubicin arm (hazard ratio [HR] = 0.771; p = 0.2842)] [7].”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tikhonova, I.A., Jones-Hughes, T., Dunham, J. et al. Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal. PharmacoEconomics 36, 507 (2018). https://doi.org/10.1007/s40273-018-0635-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-018-0635-4